Tags

Type your tag names separated by a space and hit enter

COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
Scand J Immunol. 2022 Feb; 95(2):e13131.SJ

Abstract

The role of the immune system against coronavirus disease 2019 (COVID-19) is unknown in many aspects, and the protective or pathologic mechanisms of the immune response are poorly understood. Pro-inflammatory cytokine release and a consequent cytokine storm can lead to acute respiratory distress syndrome (ARDS) and result in multi-organ failure. There are many T cell subsets during anti-viral immunity. The Th17-associated response, as a pro-inflammatory pathway, and its consequent outcomes in many autoimmune disorders play a fundamental role in progression of systemic hyper-inflammation during COVID-19. Therapeutic strategies based on immunomodulation therapy could be helpful for targeting hyper-inflammatory immune responses in COVID-19, especially Th17-related inflammation and hyper-cytokinemia. Cell-based immunotherapeutic approaches including mesenchymal stem cells (MSCs), tolerogenic dendritic cells (tolDCs) and regulatory T cells (Tregs) seem to be promising strategies as orchestrators of the immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we highlight Th17-related immunopathology of SARS-CoV-2 infection and discuss cell-based immunomodulatory strategies and their mechanisms for regulation of the hyper-inflammation during COVID-19.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Pourgholaminejad A
Department of Immunology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Pahlavanneshan S
Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Basiri M
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

MeSH

Adoptive TransferCOVID-19Cell- and Tissue-Based TherapyCytokine Release SyndromeCytokinesDendritic CellsHumansImmunomodulationMesenchymal Stem Cell TransplantationSARS-CoV-2T-Lymphocytes, RegulatoryTh17 Cells

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34936112

Citation

Pourgholaminejad, Arash, et al. "COVID-19 Immunopathology With Emphasis On Th17 Response and Cell-based Immunomodulation Therapy: Potential Targets and Challenges." Scandinavian Journal of Immunology, vol. 95, no. 2, 2022, pp. e13131.
Pourgholaminejad A, Pahlavanneshan S, Basiri M. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. Scand J Immunol. 2022;95(2):e13131.
Pourgholaminejad, A., Pahlavanneshan, S., & Basiri, M. (2022). COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. Scandinavian Journal of Immunology, 95(2), e13131. https://doi.org/10.1111/sji.13131
Pourgholaminejad A, Pahlavanneshan S, Basiri M. COVID-19 Immunopathology With Emphasis On Th17 Response and Cell-based Immunomodulation Therapy: Potential Targets and Challenges. Scand J Immunol. 2022;95(2):e13131. PubMed PMID: 34936112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges. AU - Pourgholaminejad,Arash, AU - Pahlavanneshan,Saghar, AU - Basiri,Mohsen, Y1 - 2022/01/03/ PY - 2021/12/04/revised PY - 2021/09/18/received PY - 2021/12/15/accepted PY - 2021/12/23/pubmed PY - 2022/1/27/medline PY - 2021/12/22/entrez KW - COVID-19 KW - SARS-CoV-2 KW - Th17 cells KW - Treg therapy KW - immunomodulation therapy KW - mesenchymal stem cells KW - tolerogenic dendritic cells SP - e13131 EP - e13131 JF - Scandinavian journal of immunology JO - Scand J Immunol VL - 95 IS - 2 N2 - The role of the immune system against coronavirus disease 2019 (COVID-19) is unknown in many aspects, and the protective or pathologic mechanisms of the immune response are poorly understood. Pro-inflammatory cytokine release and a consequent cytokine storm can lead to acute respiratory distress syndrome (ARDS) and result in multi-organ failure. There are many T cell subsets during anti-viral immunity. The Th17-associated response, as a pro-inflammatory pathway, and its consequent outcomes in many autoimmune disorders play a fundamental role in progression of systemic hyper-inflammation during COVID-19. Therapeutic strategies based on immunomodulation therapy could be helpful for targeting hyper-inflammatory immune responses in COVID-19, especially Th17-related inflammation and hyper-cytokinemia. Cell-based immunotherapeutic approaches including mesenchymal stem cells (MSCs), tolerogenic dendritic cells (tolDCs) and regulatory T cells (Tregs) seem to be promising strategies as orchestrators of the immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we highlight Th17-related immunopathology of SARS-CoV-2 infection and discuss cell-based immunomodulatory strategies and their mechanisms for regulation of the hyper-inflammation during COVID-19. SN - 1365-3083 UR - https://www.unboundmedicine.com/medline/citation/34936112/COVID_19_immunopathology_with_emphasis_on_Th17_response_and_cell_based_immunomodulation_therapy:_Potential_targets_and_challenges_ DB - PRIME DP - Unbound Medicine ER -